Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $35.70.
Several equities analysts recently issued reports on VRDN shares. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. TD Cowen initiated coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They issued a “buy” rating for the company. Wells Fargo & Company restated an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada upped their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th.
Read Our Latest Report on Viridian Therapeutics
Hedge Funds Weigh In On Viridian Therapeutics
Viridian Therapeutics Price Performance
NASDAQ:VRDN opened at $15.29 on Friday. The firm’s fifty day moving average is $18.27 and its two-hundred day moving average is $19.63. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -3.55 and a beta of 1.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Research analysts expect that Viridian Therapeutics will post -4.03 EPS for the current year.
Viridian Therapeutics Company Profile
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Stories
- Five stocks we like better than Viridian Therapeutics
- How to Invest in the FAANG Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- What Are Dividend Contenders? Investing in Dividend Contenders
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.